Utah Medical Products | 8-K: FY2025 Q3 Revenue: USD 9.812 M

Revenue: As of FY2025 Q3, the actual value is USD 9.812 M.

EPS: As of FY2025 Q3, the actual value is USD 0.82.

EBIT: As of FY2025 Q3, the actual value is USD 2.611 M.

Segment Revenue

• Total worldwide consolidated sales for Utah Medical Products, Inc. in 3Q 2025 were $9,812, a decrease of 1.9% compared to $10,005 in 3Q 2024.
• For the first nine months of 2025, total consolidated sales were $29,475, a decrease of 7.2% compared to $31,745 in 9M 2024.

Operational Metrics

• Gross Profit for 3Q 2025 was $5,604, a decrease of 3.4% compared to $5,802 in 3Q 2024.
• Operating Income for 3Q 2025 was $2,611, a decrease of 21.9% compared to $3,343 in 3Q 2024.
• Net Income for 3Q 2025 was $2,631, a decrease of 26.2% compared to $3,564 in 3Q 2024.
• Gross Profit Margin for 3Q 2025 was 57.1%, compared to 58.0% in 3Q 2024.
• Operating Income Margin for 3Q 2025 was 26.6%, compared to 33.4% in 3Q 2024.

Cash Flow

• Cash and investments increased to $84,267 at the end of September 30, 2025, from $82,976 at the end of 2024.

Unique Metrics

• Adjusted consolidated EBITDA for 3Q 2025 was $4,170, a decrease of 15.9% compared to $4,958 in 3Q 2024.
• Adjusted consolidated EBITDA for 9M 2025 was $13,493, a decrease of 12.7% compared to $15,447 in 9M 2024.

Outlook / Guidance

• Management expects total annual 2025 consolidated sales to be about 7% lower compared to 2024, instead of the initial projection of a 5% decrease.
• Adjusted consolidated EBITDA for the 2025 calendar year is expected to be in the range of $17 to $18 million.
• Investors are cautioned that actual events may differ from projections due to various risk factors including global economic conditions and regulatory interventions.